Overview

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-06-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

MacroGenics

Treatments:

Capecitabine
Gemcitabine
Margetuximab
Trastuzumab
Vinorelbine